Nanxiang Ge

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli et al. · The Lancet Oncology · 2019 · 465 citations

Hematological Malignancy, Medicine, Hematology +5

Comparing gene discovery from Affymetrix GeneChip microarrays and Clontech PCR-select cDNA subtraction: a case study

Wuxiong Cao, Charles B. Epstein, Hong Liu et al. · BMC Genomics · 2004 · 84 citations · Full text

Development of Robust Multivariate Calibration Models

Edward V. Thomas, Nanxiang Ge · Technometrics · 2000 · 40 citations

Precision Agriculture, Environmental Monitoring, Engineering +22

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli et al. · Blood · 2018 · 36 citations

Lack of Effect of DX-619, a Novel Des-Fluoro(6)-Quinolone, on Glomerular Filtration Rate Measured by Serum Clearance of Cold Iohexol

Nenad Sarapa, Prachi Wickremasingha, Nanxiang Ge et al. · Antimicrobial Agents and Chemotherapy · 2007 · 18 citations · Full text

Healthy Subjects, Pharmacotherapy, Antimicrobial Chemotherapy +18